Obefazimod may improve UC symptoms as early as week 1
-
November 10
Pooled phase 3 ABTECT data presented at ACG 2026 showed gains building through week 8, including after JAK inhibitor and other advanced therapy failure.
BROWSE BY TOPICS
Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist
-
August 3
-
by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR
GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.
Bridging the rural divide: Building a motility center in a critical access hospital
-
August 3
-
by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF
“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”
Is professional coaching worth it? A practical guide for early-career gastroenterologists
-
August 3
-
by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG
Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.
The Latest
Two Barrett’s biomarkers tied to progression, but neither shown superior
-
by Julia Cipriano
Both tests had negative predictive values above 90%, which the authors said supports longer surveillance intervals for low-risk patients.
Obefazimod may improve UC symptoms as early as week 1
-
by Julie Greenbaum
Pooled phase 3 ABTECT data presented at ACG 2026 showed gains building through week 8, including after JAK inhibitor and other advanced therapy failure.
Diffuse esophageal eosinophilia tied to more severe EoE, lower steroid response
-
by Julie Greenbaum
Among 395 patients treated with topical corticosteroids, 51% with diffuse involvement had a histologic response, compared with 67% to 70% of those with localized disease.
Global study links liver transplant to survival gains in severe ACLF
-
by Julia Cipriano
Among patients declined for transplant, 88% with ACLF grade 3 died within a year of enrollment; among grade 3 recipients, 21% died within a year of surgery.
Upadacitinib ranked first for UC induction in network meta-analysis
-
by Julie Greenbaum
Interleukin-23 p19 inhibitors ranked most favorably for serious adverse events and discontinuations across 33 trials, though the authors rated confidence in the safety estimates as lower.
Esophagus
Liver
Small bowel
Stomach
Obesity
Alcohol-related liver disease
Biliary tract cancer
Colorectal cancer
Esophageal cancer
Liver cancer
Celiac disease
Diarrhea and constipation
Diet and nutrition
Eosinophilic GI diseases
Eosinophilic esophagitis
Hepatic encephalopathy
IBD
Crohn's disease
Ulcerative colitis
IBS
Infections
C. diff
MASLD and MASH
Short bowel syndrome
Pancreatic diseases and conditions
GERD and Barrett’s esophagus
Career & professional development
Diversity, equity, and inclusion
Health, wellness, and burnout
Patient advocacy and equity
Practice management
Coding, coverage, and reimbursement
Technology & innovation
Endoscopy